• Mashup Score: 0
    Episode 1: When Is CAR T-Cell Therapy the Answer? - 11 month(s) ago

    Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what’s next in this rapidly advancing field.

    Source: Medscape
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MedscapeOnc
      MedscapeOnc

      Drs @AmeliaLangston and @MelodySmithMD provide an overview of #CARTcellTherapy, the products available, potential complications, and what's next in this rapidly advancing field. #CancerTreatment #Immunotherapy https://t.co/DgOdZkJyuL

  • Mashup Score: 0
    Episode 1: When Is CAR T-Cell Therapy the Answer? - 12 month(s) ago

    Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what’s next in this rapidly advancing field.

    Source: Medscape
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Medscape
      Medscape

      Drs @AmeliaLangston and @MelodySmithMD provide an overview of #CARTcellTherapy, the products available, potential complications, and what's next in this rapidly advancing field. #Immunotherapy #CancerTreatment https://t.co/u73y7MoAMy

  • Mashup Score: 0
    CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD - 12 month(s) ago

    iFrame is not supported! CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD By Reiner Brentjens, MD, PhD from Roswell Comprehensive Cancer Center The basic platform on which we have been working for over two decades involves taking a patient’s own immune cells, T-cells, and gene…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Promising preclinical results of CAR T-cell therapy against small cell lung cancer from Renier Brentjens, MD, PhD, on OncologyTube! Watch Here: https://t.co/EPFPdXy7lQ @BrentjensRenier @roswellpark #SCLC #CARTcellTherapy https://t.co/YgVrWmcdej

  • Mashup Score: 0
    Bispecific CAR-T induces durable responses in advanced non-Hodgkin lymphoma - 1 year(s) ago

    Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results. The novel cellular therapy exhibited a manageable safety profile, with no reports of high-grade cytokine release syndrome or neurotoxicity, findings presented at American Association for Cancer Research

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      A novel cell therapy induced objective response among 10 of 11 patients with relapsed/refractory B-cell lymphoma, data presented at #AACR23 showed. @dgsomucla #CARTcelltherapy https://t.co/B6KTNK8sic

  • Mashup Score: 0
    Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Connor Johnson MD - 1 year(s) ago

    Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy treatment that has transformed the landscape for those with relapsed refractory hematologic malignancies. It is a treatment where we take white blo…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Groundbreaking research! 🔬🙌🏼 Check out this incredible video of Dr. Connor Johnson sharing the results of his longitudinal study on CAR T-Cell Therapy. 🎥🔬 Watch the video now on OncologyTube! 👀💻 https://t.co/yi5o2S85XY @pconnorjohnson @MassGeneralNews #CARTcellTherapy https://t.co/A8FdPOw6se

  • Mashup Score: 0
    Treatment After CAR T-Cell Therapy for People with Diffuse Large B-Cell or Grade 3B Follicular Lymphoma | SWOG - 1 year(s) ago

    Clinical Trial Summary (S2114) What is the purpose of this clinical trial? This study will test treatment for people with diffuse large B-cell lymphoma (DLBCL) or certain types of follicular lymphoma. These cancers affect B-cells, which are a type of white blood cell that normally helps your body fight infection. CAR…

    Source: www.swog.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SWOG
      SWOG

      Study S2114 tests which drug treatment works best after CAR T-cell therapy for diffuse large B-cell lymphoma or grade 3B #follicular #lymphoma. It will also test the safety of the drugs after #CARTcelltherapy. Visit https://t.co/KUX8Ccx4S1. Or call 1-800-4-CANCER. @LLSusa #hemonc https://t.co/7QQsPIDXA3

  • Mashup Score: 0
    Community physicians play essential role in long-term care after CAR-T - 1 year(s) ago

    Despite an overall positive safety outlook, the scope of potential toxicities related to chimeric antigen receptor T-cell therapy remains unclear due to lack of long-term follow-up.It has been barely a decade since the modality produced the first reported remission in a child with B-cell acute lymphoblastic leukemia.

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      CELL THERAPY NEXT: Community physicians play essential role in long-term care after CAR-T. https://t.co/fC9S5FTXpg @seattlechildren @DanaFarber @Penn #carTcellTherapy #HemOnc #OncAlert #MedEd

Load More